Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...

Developers summoned; Xerotech on the brink; Glencore eyes Pallas Green sale; CRH invests in 3D; Mounjaro arrives; and O’Hara ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

The 19-year-old phenom, who is set to finally take over as a starter in the 2025 season, said he has been bullied by his famous uncles, Peyton and Eli, and they have even given him wedgies.

Federal technology services contractor Harmonia Holdings Group has acquired Maveris for an undisclosed sum to strengthen its cybersecurity capabilities and expand relationships with other ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

Boston Globe Media has acquired Boston Magazine from a Philadelphia-based publisher, adding to a regional newsroom portfolio that includes The Boston Globe, Boston.com, and STAT News.

Hindustan Unilever has agreed to acquire beauty startup Minimalist for about $342 million, as the consumer goods giant seeks to expand in India’s fast-growing premium skincare market.

The Philadelphia 76ers were expected to challenge for the NBA Championship this season after signing Paul George in the summer to team up with Tyrese Maxey and Joel Embiid. Unfortunately, reality ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s ...

Eli Lilly's Q4 FY24 guidance adjustment is due to supply chain factors, not demand, creating an attractive buying opportunity with a 'Buy' rating. Despite a modest 0.6% revenue reduction ...